Claroid Pharmaceuticals has filed its draft prospectus with SEBI for an IPO, including a fresh issue of 74.50 lakh shares. The funds will support a new ₹167.97 crore manufacturing facility in Ahmedabad. Investors will likely focus on the company's aggressive growth trajectory and its significant reliance on export markets in Africa.
Funding the Ahmedabad Expansion
Claroid Pharmaceuticals has officially submitted its draft red herring prospectus (DRHP) to the Securities and Exchange Board of India (SEBI). The company intends to raise capital through an Initial Public Offering (IPO) composed of a fresh issue of 74.50 lakh shares and an offer for sale (OFS) of 51.50 lakh shares. The primary goal of this fundraise is to finance a new, high-capacity manufacturing facility in Ahmedabad. The project is budgeted at ₹167.97 crore and aims to establish a production capacity of 15 lakh units per month. The facility will be dedicated to injectable and ophthalmic product lines, marking a step to diversify beyond the company's existing production of tablets, capsules, and ointments at its current Pirana site.
Revenue Growth and Export Strategy
The company has reported a rapid increase in financial performance over the last two years. Operational revenue climbed to ₹169.72 crore in FY26, a significant jump from ₹62.98 crore in FY24, representing a compound annual growth rate (CAGR) of 64.13 percent. A substantial portion of this business is driven by international trade, with a strong focus on African markets. Nigeria currently stands as the company’s largest export destination. To support its international operations, Claroid utilizes a distribution network spanning over 30 partners across Africa and maintains GMP certifications from regulatory bodies in regions including Rwanda, Ghana, and Zanzibar.
Investor Monitorables
For potential investors, the scale of the planned expansion is a critical factor to track. The budgeted project cost of ₹167.97 crore is quite large relative to the company’s revenue of ₹169.72 crore in FY26. This level of investment carries execution risk, as the company must ensure the project stays on budget and on schedule to avoid delays in capacity addition. Additionally, the company’s heavy reliance on export markets—specifically Nigeria—exposes it to risks related to currency fluctuations and geopolitical changes in those regions. Managing these factors while competing in the highly fragmented Indian pharmaceutical sector will be essential for the company's long-term business sustainability. The IPO process is being managed by Oneview Corporate Advisors and Valmiki Leela Capital, and the next important milestones will be the regulatory review by SEBI and any updates on the final pricing of the issue.